Hook & Thesis
UiPath has finally pulled back into my buy zone. The shares are hovering around $11.25 after a wobbly start to 2026; that price gets you exposure to a leading automation platform transforming toward agentic AI orchestration at a valuation that is modest relative to its free cash flow generation. I view the current set-up as an asymmetric trade: upside comes from product-led adoption of agentic automation and continued monetization improvements; downside is contained by a clearly defined stop and the fact that the company is cash-flow positive on a near-term basis.
Concretely: buy at $11.25, set a protective stop at $9.50, and take a primary target at $14.24 over the mid-term (45 trading days). The risk-reward on those levels is acceptable to me: roughly 26.6% upside to the target vs about 15.6% downside to the stop.
What UiPath Does and Why the Market Should Care
UiPath builds software to automate business processes. Historically known for robotic process automation (RPA), the company has been pivoting its product stack toward "agentic" automation - orchestration layers that coordinate multiple AI agents and legacy automation to perform complex workflows. That shift matters because companies are trying to reduce manual toil across finance, security, claims, procurement, and contact centers. Agentic execution layers can materially cut manual effort on expensive, repetitive tasks and surface ROI more quickly than one-off ML pilots.
The market cares because this is a scalability story: once an automation runs end-to-end, the incremental margin on that automation is high. UiPath is positioning itself as the orchestration hub for those automations, and recent product announcements and a Microsoft partnership (security automation) suggest it is aiming to be embedded into enterprise workflows, not just sold as point tools.
What the Numbers Say
Here are the most relevant headline figures to anchor the trade thesis:
| Metric | Value |
|---|---|
| Current price | $11.25 |
| Market cap | $5.89B |
| EPS (ttm) | $0.54 |
| Price / Earnings | ~21x |
| Price / Sales | 3.66x |
| Enterprise value | $5.02B |
| EV / Sales | 3.12x |
| EV / EBITDA | 27.4x |
| Free cash flow (annual) | $352.16M |
| 52-week range | $9.38 - $19.84 |
Two arithmetic points matter for valuation: the company trades at roughly 21x earnings and about 3.66x price-to-sales. With free cash flow of $352M on a market capitalization near $5.89B, implied free cash flow yield is about 6.0%. That yield, plus positive operating metrics (current ratio ~2.48), makes the valuation reasonable for a software business that is already producing cash and digging into AI-driven expansions.
Technical & Sentiment Context
Technically, the stock sits just above its 10-day simple moving average ($11.215) but below the 20-day ($11.557) and 50-day ($11.85) averages. Momentum indicators are muted: RSI is 46 (neutral) and the MACD histogram is slightly negative, implying no strong trend yet. Short interest has climbed materially: the March 13, 2026 settlement shows roughly 93.99M shares short, but days-to-cover is low (~1.74), so a squeeze is possible but not guaranteed. Average daily volume over 30 days is large (~36M shares), which helps with order execution around the proposed entry and exit points.
Valuation Framing
UiPath is no longer priced like a hyper-growth SaaS darling; multiples have compressed with the pullback. EV/Sales near 3.1x and P/E around 21x place the stock in the more conservative part of the growth spectrum. That said, EV/EBITDA of 27x suggests the market expects meaningful future margin expansion or earnings growth to justify the current EV. The way to outpace that expectation is for agentic automation to meaningfully increase seat penetration, expand average contract values, or increase platform monetization (e.g., orchestration or agent marketplace fees).
Catalysts to Watch (2-5)
- 03/25/2026 product launches - adoption signals and early customer case studies that quantify manual-effort reduction and ROI.
- Microsoft security automation partnership progress - joint wins would accelerate enterprise trust and top-line growth.
- Quarterly results showing continued free cash flow strength or better-than-expected ARR expansion - a beat could reset multiples.
- Macro rotation back into AI and software names - a broader sentiment improvement would reduce valuation discounting.
Trade Plan (actionable)
Entry: $11.25 (market or limit as you prefer).
Stop loss: $9.50 (hard stop - logical technical level under the current 52-week low buffer and below the recent consolidation).
Target: $14.24 (primary target - aligns with consensus analyst targets and provides ~26.6% upside from entry).
Horizon: primary plan is a mid-term swing - mid term (45 trading days) - to give time for catalysts (product traction and one earnings or business update) to be priced in. If adoption evidence is strong and institutional demand returns, I would hold into a longer-term re-rate - long term (180 trading days) - targeting a move toward prior highs (near $19.84) as a stretch scenario.
Position sizing guidance: this is a tactical trade, not a full conviction long. Size to the portion of your portfolio allocated to medium-risk growth-swing ideas and account for about 12-16% downside risk to the stop from entry.
Risks and Counterarguments
- Execution risk on agentic products: New product launches do not guarantee enterprise adoption. Large customers can be slow to deploy new orchestration layers and may treat agentic AI with caution.
- Growth deceleration: Some coverage notes a 13% revenue growth rate and downgrades; if revenue growth continues to slow, multiples could contract further and the target may not be reached.
- Competitive pressure: Big cloud and software vendors (including native automation features inside large suites) can compress pricing and win share where UiPath is not deeply entrenched.
- High short interest & event risk: elevated short volumes create volatile price action around earnings or product announcements; while a squeeze could help, negative news could be amplified.
- Macro/tech sentiment: a broader risk-off in large-cap tech names or a repeat of the AI "trough of disillusionment" could keep multiples depressed despite improving fundamentals.
Counterargument (why skeptics are right)
Critics will point to slower revenue growth and analyst downgrades as evidence that UiPath is past its high-growth phase. If the market re-prices the company to a lower long-run growth multiple because agentic automation fails to translate into new revenue streams quickly, the stock could underperform for an extended period. That case is plausible and is precisely why a protective stop and moderated position size are essential.
What Would Change My Mind
I would abandon the long thesis if any of the following occur: (1) a quarterly release showing structural revenue and ARR deceleration below 10% growth without commensurate margin improvement; (2) material customer churn or loss of a marquee partnership; or (3) guidance that implies an inability to monetize agentic features meaningfully over the next 4 quarters. Conversely, a sustained acceleration in ARR and clear platform monetization metrics (higher ACV per customer, more seats sold, or marketplace fees) would convince me to add size and extend the target toward previous highs.
Conclusion - Clear Stance
I am long UiPath at $11.25 with a stop at $9.50 and a primary target of $14.24. The trade is a measured, mid-term swing (45 trading days) that rests on two core ideas: the company is cash-flow positive at a reasonable multiple, and agentic automation is an emerging, high-leverage product theme that UiPath is positioned to benefit from. Execution and adoption are the key risks; trade size accordingly and use the stop to control downside.
Note: Monitor product traction updates (customer case studies, partnership wins) and the next quarterly report closely; these will be the decisive inputs to the trade's success.